Oncology Brothers: Practice-Changing Cancer Discussions

Oncology Brothers
  • 4.9 (57)
  • Medicine

The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients. Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format. Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice. Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities. If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at info@oncbrothers.com Privacy Policy: https://oncbrothers.com/privacy-policy Terms & Conditions: https://oncbrothers.com/terms-and-conditions

  1. 21h ago ·  Video

    Managing Toxicities of Therapies in Polycythemia Vera (PV) / Essential Thrombocythemia (ET)

    Welcome back to the Oncology Brothers podcast! In this episode, we were joined by the MPN specialists Drs. Brandi Reeves and Naveen Pemmaraju, to discuss the treatment options for polycythemia vera (PV) and essential thrombocythemia (ET).   We dived deep into the side effect profiles and management strategies for key treatments, including: Hydroxyurea: Learnt about dosing strategies, monitoring, and the importance of managing acute and chronic side effects such as leg ulcers and skin cancer risks Ropeginterferon alfa-2b: Discover the benefits and potential side effects, including flu-like symptoms and neuropsychiatric issues, and how to approach dosing for patients with pre-existing conditions Ruxolitinib: Understand the common side effects, including myelosuppression and weight gain, and the critical importance of tapering off the medication rather than stopping abruptly Rusfertide: Get insights into this new hepcidin mimetic and its promising role in managing PV, along with potential side effects to monitor   Join us for a comprehensive tox check discussion that aims to equip healthcare professionals with clinical pearls for managing these treatments effectively.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o    Follow us on social media: X/Twitter: ⁠https://x.com/oncbrothers⁠  ⁠Instagram: ⁠https://www.instagram.com/oncbrothers⁠  Website: ⁠https://oncbrothers.com/⁠    Subscribe for more insights and updates from the Oncology Brothers! #PolycythemiaVera, #MPN, #EssentialThrombocythemia, #CytotoxicTherapies, #OncologyBrothers

    Managing Toxicities of Therapies in Polycythemia Vera (PV) / Essential Thrombocythemia (ET)

  2. 2d ago ·  Video

    VERIFY: FDA Approval of Rusfertide in Polycythemia Vera (PV) - Dr. Andrew Kuykendall

    Welcome to the Oncology Brothers podcast! In this episode, we dived into the recent approval of rusfertide for polycythemia vera, based on the findings from the VERIFY study. We were joined by Dr. Andrew Kuykendall, an MPN specialist from the Moffitt Cancer Center, who shared insights on the drug's mechanism of action as a hepcidin mimetic and its clinical implications.   Key topics discussed included: The unique challenges of managing polycythemia vera, with balancing of erythrocytosis and iron deficiency The design and findings of the VERIFY study, highlighting the significant reduction in the need for phlebotomy among patients treated with rusfertide The potential for individualized patient care and the integration of rusfertide with existing cytoreductive therapies Insights into dosing, side effects, and the drug's impact on patient quality of life   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o    Follow us on social media: X/Twitter: https://x.com/oncbrothers  ⁠Instagram: https://www.instagram.com/oncbrothers  Website: https://oncbrothers.com/    Join us as we explore how rusfertide can change the treatment landscape for polycythemia vera and improve patient outcomes. Don't forget to like, subscribe, and hit the notification bell for more episodes! #Rusfertide, #PolycythemiaVera, #VERIFYstudy, #MPN, #Hematology

    VERIFY: FDA Approval of Rusfertide in Polycythemia Vera (PV) - Dr. Andrew Kuykendall

  3. 4d ago ·  Video

    Polycythemia vera (PV) and Essential thrombocythemia (ET) Treatment Algorithm: Dr. Aaron Gerds

    Welcome to the Oncology Brothers podcast! In this episode, we are joined by Dr. Aaron Gerds, a hematologist from the Cleveland Clinic, to discuss the current treatment algorithms for myeloproliferative neoplasms (MPNs), specifically focusing on polycythemia vera (PV) and essential thrombocythemia (ET).   Join us as we delved into: The diagnostic criteria for PV and ET, including the significance of JAK2 mutations and erythropoietin (EPO) levels The role of bone marrow biopsies in diagnosing and managing these conditions Treatment options for PV, including hydroxyurea, ropeginterferon alfa-2b, and ruxolitinib, as well as the approval of rusfertide The importance of risk stratification based on patient age and history of thrombosis The management of side effects associated with various treatment options The clinical utility of monitoring JAK2 allele burden and its implications for patient management Insights into the treatment landscape for ET, including the use of antiplatelet therapy and the role of acquired Von Willebrand disease   Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode provides valuable insights into the complexities of managing PV and ET.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o    Follow us on social media: ⁠X/Twitter: https://x.com/oncbrothers  ⁠Instagram: https://www.instagram.com/oncbrothers  Website: https://oncbrothers.com/    Don't forget to like, subscribe, and hit the notification bell for more episodes on the latest in hematological and oncological care! #PolycythemiaVera, #EssentialThrombocythemia, #MPN, #JAK2, #OncologyBrothers

    Polycythemia vera (PV) and Essential thrombocythemia (ET) Treatment Algorithm: Dr. Aaron Gerds

  4. Aug 27 ·  Video

    Multiple Myeloma Management - Partners in Practice with Dr. Ajai Chari Team from UCSF

    Welcome to the Oncology Brothers podcast! In this episode of our Partners in Practice series, we dived into the world of multiple myeloma treatment. We had the opportunity to engage with the dedicated team from UCSF, including Dr. Ajai Chari, a myeloma specialist, nurse practitioner Samantha Shenoy, NP, and clinical nurse Jenny Truong, RN.   In this insightful discussion, we covered: The current standard of care for newly diagnosed multiple myeloma patients, focusing on quadruple therapy The role of anti-CD38 therapies like daratumumab and isatuximab in treatment regimens Patient expectations regarding side effects and the importance of supportive care The dynamics of teamwork in oncology, emphasizing communication and collaboration among healthcare professionals   Whether you're a healthcare professional, a patient, or simply interested in the latest advancements in cancer care, this episode offers valuable insights into the complexities of treating multiple myeloma.     Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Follow us on social media: X/Twitter: https://x.com/oncbrothers  ⁠Instagram: https://www.instagram.com/oncbrothers  Website: https://oncbrothers.com/  Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers! #MultipleMyeloma, #QuadTherapy, #Daratumumab, #Isatuximab, #OncologyBrothers

    Multiple Myeloma Management - Partners in Practice with Dr. Ajai Chari Team from UCSF

  5. Aug 25 ·  Video

    HERIZON-GEA-01: FDA Approval of Zanidatamab + Tislelizumab for HER2+ Esophageai/GEJ/Gastric Adeno

    We had a chance to dive into one of the most significant advancements in the treatment of HER2-positive gastroesophageal junction (GEJ) and gastric adenocarcinoma. In this episode, we discussed the groundbreaking HERIZON-GEA-01 study that led to the approval of zanidatamab, a novel bispecific HER2-directed antibody.   We welcomed Dr. Nataliya Uboha, a GI medical oncologist from the University of Wisconsin, who shared her insights on the study's design, findings, and the implications for clinical practice. Learn about the importance of biomarker testing, the mechanism of action of zanidatamab, and how it compares to traditional therapies like trastuzumab.   Key topics covered in this episode: Overview of the HERIZON-GEA-01 study and its findings Mechanism of action of zanidatamab Comparison of treatment regimens and overall survival benefits Management of side effects, including diarrhea and infusion reactions The role of PD-L1 testing in treatment decisions   Whether you're a healthcare professional or simply interested in the latest in oncology, this episode provides valuable insights into the evolving landscape of treatment for HER2-positive upper GI malignancies.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: ⁠X/Twitter: https://x.com/oncbrothers  ⁠Instagram: https://www.instagram.com/oncbrothers  Website: https://oncbrothers.com/    Don't forget to like, subscribe, and check out our other discussions on FDA approvals, treatment algorithms, and challenging cases!   #GastricCancer, #HER2positive, #Zanidatamab, #HERIZONGEA01, #OncologyBrothers

    HERIZON-GEA-01: FDA Approval of Zanidatamab + Tislelizumab for HER2+ Esophageai/GEJ/Gastric Adeno

  6. Aug 24 ·  Video

    Rapid Fire Rounds - Multiple Myeloma Management with Dr. Joseph Mikhael

    Welcome to the Oncology Brothers podcast and our new series, Rapid Fire Rounds! In this episode, we were joined by Dr. Joseph Mikhael, a myeloma specialist from the City of Hope, to answer 10–12 community-sourced questions on multiple myeloma management.   The panel covers: Frontline therapy: Quadruplet therapy, carfilzomib vs bortezomib, and high-risk disease definitions Maintenance strategies: Lenalidomide alone vs daratumumab-lenalidomide vs carfilzomib-lenalidomide, with insights from the ENDURANCE, ATLAS trials Relapsed/refractory disease: Sequencing CAR T-cell therapy, bispecific antibodies (teclistamab + daratumumab), and the newly approved cereblon modulators (CELMoDs) like mezigdomide CAR-T logistics: The critical distinction between holding therapy (pre-collection) and bridging therapy (post-collection) Supportive care: IVIG, antiviral/antifungal prophylaxis, and monitoring for ICANS MRD testing: Current role in clinical practice and its use as an endpoint for drug approval   This episode is packed with practical, actionable insights for community oncologists managing myeloma day-to-day.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Follow us on social media: ⁠X/Twitter: https://x.com/oncbrothers  ⁠Instagram: https://www.instagram.com/oncbrothers  Website: https://oncbrothers.com/    Don't forget to like, subscribe, and hit the notification bell for more Rapid Fire Rounds from the Oncology Brothers! #MultipleMyeloma, #CARTtherapy, #MRD, #CELMoD, #OncologyBrothers

    Rapid Fire Rounds - Multiple Myeloma Management with Dr. Joseph Mikhael

  7. Aug 20 ·  Video

    EXCALIBER-RRMM - Iberdomide/Dara/Dex FDA Approval for R/R Multiple Myeloma: Dr. Sagar Lonial

    Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Sagar Lonial, a myeloma specialist from the Emory University, to discuss the recent FDA approval of iberdomide, a novel cereblon modulator (CELMoDs), in combination with daratumumab and dexamethasone for the treatment of relapsed and refractory multiple myeloma.   Join us as we dive into: The significance of the EXCALIBER-RRMM study that led to the approval of iberdomide What makes cereblon modulators different from existing immunomodulatory agents (IMiDs) and their potential benefits The study design, findings, and the implications of minimal residual disease (MRD) as a primary endpoint for approval Who the ideal candidates for iberdomide are and how it fits into the current treatment landscape The side effect profile of iberdomide compared to traditional therapies and management strategies Insights on monitoring disease status and the future of cereblon modulators in combination with other therapies   This episode is packed with valuable information for healthcare professionals and anyone interested in the latest advancements in multiple myeloma treatment. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Follow us on social media: X/Twitter: https://x.com/oncbrothers  Instagram: https://www.instagram.com/oncbrothers  Website: https://oncbrothers.com/    Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers! #CELMoDs, #MultipleMyeloma, #EXCALIBERstudy, #MRD, #OncologyBrothers

    EXCALIBER-RRMM - Iberdomide/Dara/Dex FDA Approval for R/R Multiple Myeloma: Dr. Sagar Lonial

  8. Aug 17 ·  Video

    Managing Toxicities of Androgen Receptor Pathway Inhibitor (ARPI) in Prostate Cancer

    Welcome to the Oncology Brothers podcast! In this episode, we discussed the world of androgen receptor pathway inhibitors (ARPIs) in prostate cancer as part of our Tox Check series. Joined by esteemed guests Dr. Alicia Morgans, a GU medical oncologist from Dana-Farber Cancer Institute, and Dr. Christopher M. Pieczonka, a urologist from US Urology Partners, the discussion covered the common side effects associated with ARPIs, including cardiac issues, cognitive changes, and more.   Key topics included: An overview of approved ARPIs, focusing on abiraterone, apalutamide, darolutamide, and enzalutamide The importance of monitoring side effects and strategies to mitigate them Insights from recent studies, highlighting the impact of these medications on patient quality of life A discussion on the role of shared decision-making in treatment options for prostate cancer patients   Whether you're a healthcare professional or someone interested in prostate cancer treatment, this episode aims to equip you with valuable knowledge to better manage patient care.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Follow us on social media: •⁠  ⁠X/Twitter: https://x.com/oncbrothers  •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers  •⁠  Website: https://oncbrothers.com/    Don't forget to like, subscribe, and hit the notification bell for more insightful discussions from the Oncology Brothers!   #ProstateCancer, #ARPI, #SideEffectManagement, #SharedDecisionMaking, #OncologyBrothers

    Managing Toxicities of Androgen Receptor Pathway Inhibitor (ARPI) in Prostate Cancer
See All (100)

4.9
out of 5
57 Ratings

About

The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients. Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format. Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice. Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities. If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at info@oncbrothers.com Privacy Policy: https://oncbrothers.com/privacy-policy Terms & Conditions: https://oncbrothers.com/terms-and-conditions

Information

You Might Also Like